|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Develops personalized cell therapies for aesthetic, medical, and scientific applications |
|
| Management |
| David Pernock, Chairman & CEO; Declan Daly,
Chief Operating Officer and Chief Financial Officer; Elizabeth A. Browning,
Executive Vice President, Marketing;
John Maslowski,
Vice President, Operations;
Jeanne Novak, Ph.D.,
Acting Vice President, Clinical/Regulatory Operations;
James Merritt, M.D.,
Chief Medical Advisor;
Laura Campbell,
Vice President, Human Resources and Planning;
Karen Donhauser,
Vice President, Quality |
| |
|
|
|
|
|
|
|
| Keywords |
| cell therapies, aesthetic, autologous, skin |
|
|
|
| Description |
|
Fibrocell Science Inc. develops personalized autologous cell therapies for aesthetic, medical, and scientific applications. The Company's lead product, LAVIV™ (azficel-T), is the first and only personalized aesthetic cell therapy approved by the FDA for the improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults. The Fibrocell Science patented process involves the extraction of a patient's own natural fibroblasts, cells that contribute to the formation of connective tissue fibers, from a small sample of cells behind the ear and then being multiplied, purified, cryopreserved, and re-injected throughout multiple treatment sessions. These matrix fibers harbor regenerative effects such as improved skin texture, collagen secretion, and wound healing. This later-stage biotechnology company is planning to continue studies for additional aesthetic and therapeutic indications for azficel-T, and is collaborating with UCLA in its research. |
|
| Technology / Differentiation |
Fibrocell Therapy is a late stage personalized cell therapy. In the Fibrocell Science patented process, a patient?s own natural fibroblasts are extracted, multiplied, purified, cryopreserved and re-injected as personalized therapy. Fibroblasts are cells that contribute to the formation of connective tissue fibers. These matrix fibers are critical to the strength and elasticity of the skin.
Broadly, the regenerative effects of fibroblasts include:
The ability to synthesize the extracellular matrix components and, thus, to improve skin texture;
the secretion of matrix fibers, including collagen; and
playing a critical role in wound healing and tissue repair.
The Company prepares the azficel-T through a process that begins with removing a small sample of cells from behind a patient?s ear and sending that sample to the Fibrocell cGMP facility. The process expands fibroblasts into hundreds of millions of new cells, which are then formulated into an autologous cellular therapy. Cells are frozen and used for multiple treatment sessions. The therapy is reintroduced into the patient?s skin by injection, which the Company believes results in an increase in the local fibroblast population, collagen formation and assists the body?s own regenerative healing process. In controlled clinical studies, a significant improvement in the appearance of nasolabial fold wrinkles was observed after injecting azficel-T, brand name laViv.
Regenerative fibroblast cells may have potential in use for broad aesthetic, medical and scientific applications. The Fibrocell Therapy for aesthetics, azficel-T, brand name Laviv, has been approved by the FDA for the treatment of moderate to severe nasolabial fold wrinkles. Fibrocell Science, Inc. is planning to continue studies for additional aesthetic and therapeutic indications for azficel-T. |
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
